Company Overview
 |
DiaMedica Inc. is a publicly traded (TSX-V:DMA) clinical stage biopharmaceutical company focused on the discovery and development of novel therapies to treat diabetes and the complications associated with diabetes. |
Latest News
|
01-May-2013 – Minneapolis, MN DiaMedica Inc. (TSX-V:DMA), announces the commencement of its Phase I/II trial with first in human dosing of DM-199; a recombinant protein therapy for the treatment of diabetes and associated complications. As described in the April 8th 2013 press release, the study is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of DM-199 in 36 healthy volunteers and in 40 Type 2 diabetic patients. |
|
|
08-Apr-2013 – Minneapolis, MN DiaMedica Inc. (TSX-V:DMA), is pleased to announce it has received regulatory approval to commence an anticipated 76 subject Phase I/II clinical trial for DM-199. The clinical trial, to be conducted in the Netherlands, is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of DM-199 in 36 healthy volunteers and in 40 T2D patients. Data from this trial will also support future DM-199 clinical trial regulatory filings for Type 1 and 2 diabetes and in other potential indications. |
|
DiaMedica Inc. Announces Completion of $4.6 Million Prospectus Offering 22-Mar-2013 – Minneapolis, MN DiaMedica Inc. (TSX-V:DMA), is pleased to announce the completion today of its previously announced short form prospectus offering (the “Offering”). Pursuant to the Offering, DiaMedica issued a total of 5,111,175 units (the "Units") at a price of $0.90 per Unit for aggregate gross proceeds of approximately $4.6 million. |